FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - October 10, 2025 59 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify patients with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukaemia June 2, 2022 Selpercatinib Shows Durable Efficacy in RET Fusion–positive NSCLC August 27, 2020 ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany May 8, 2024 2021/22 in review: Charity looks to the future with ambitious new... July 21, 2022 Load more HOT NEWS EMA Recommends Extension of Indications for Osimertinib Multiple Myeloma Awareness Month: Inequity and Disparities in Multiple Myeloma Diagnosis,... FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma Shelter Cat Who Battled Breast Cancer Seeks Fellow Survivor to Give...
